Latest Biotech News

Researchers at MUSC Hollings Cancer Center published preclinical data showing that a monoclonal antibody targeting secreted frizzled‑related protein 2 (SFRP2) reduced primary triple‑negative...

Triana Biomedicines announced an oversubscribed $120 million Series B to advance its molecular glue degrader pipeline, including lead candidate TRI‑611 aimed at ALK‑driven non‑small cell lung...

Freenome agreed to merge with a SPAC to take the Bay Area liquid‑biopsy developer public with roughly $330 million in proceeds, including a $240 million PIPE commitment. The deal accelerates...

The Advisory Committee on Immunization Practices voted to remove the long‑standing universal hepatitis B vaccine recommendation at birth for infants whose mothers test negative, instead urging...

The FDA named Tracy Beth Høeg as acting director of the Center for Drug Evaluation and Research amid rapid leadership turnover at CDER. Høeg, an epidemiologist who worked on high‑profile vaccine...

Natera agreed to acquire Foresight Diagnostics for $275 million upfront plus up to $175 million in earnouts to integrate PhasED‑Seq phased‑variant technology into Natera’s Signatera MRD platform....

Royalty Pharma agreed to provide up to $275 million to Denali tied to potential approval of tividenofusp alfa, giving Denali contingent capital while the FDA delays a regulatory decision. The...

Triana Biomedicines closed an oversubscribed $120 million Series B to advance TRI‑611, a molecular‑glue degrader targeting ALK‑driven non‑small cell lung cancer, into clinical development. The...

Praxis Precision Medicines stopped its Phase 2/3 EMBOLD trial early after an interim analysis showed statistically robust efficacy for relutrigine in a rare epilepsy indication. The company said...

Encoded Therapeutics reported Phase 1/2 Dravet syndrome gene‑therapy data showing a 78% reduction in seizures linked to ETX101, moving the program toward a pivotal study next year. The company...

Terray Therapeutics announced it achieved the first discovery milestone under its multi‑target collaboration with Bristol Myers Squibb, validating its Experimentation Meets Machine Intelligence...

Ginkgo Bioworks secured a four‑year, $47 million contract to design and build an automated phenotyping platform for the Pacific Northwest National Laboratory and its Environmental Molecular...

An advisory swirl over newborn hepatitis B vaccinations culminated this week in procedural chaos and a contentious policy shift. Early in the week the CDC’s Advisory Committee on Immunization...

Twelve former FDA commissioners publicly condemned proposed vaccine-policy changes and accused the agency’s biologics chief of threatening longstanding regulatory standards, publishing their...

Capricor Therapeutics reported positive top-line Phase III data for its cell therapy deramiocel in Duchenne muscular dystrophy, prompting a dramatic market reaction and a strategic financing push....

Regulatory friction and financing maneuvers converged for Denali Therapeutics this week. The FDA placed a hold on Denali’s planned Phase 1 study for a Pompe-disease candidate, requesting protocol...

UniQure warned investors that the FDA’s recent feedback on its Huntington’s disease gene therapy will likely delay an anticipated approval filing and complicate its regulatory path. The company...

Natera acquired Foresight Diagnostics for $275 million upfront plus up to $175 million in milestones to integrate high-sensitivity phased-variant ctDNA technology into its Signatera minimal...

Triana Biomedicines closed an oversubscribed $120 million Series B to advance its molecular-glue degrader platform and push lead candidate TRI-611 toward the clinic for ALK-driven non–small-cell...

OTR Therapeutics, a Shanghai-based biotech, closed a $100 million Series A to build a diversified R&D and asset portfolio, with participation from Pfizer Ventures. The company said it will combine...